Medtronic's INFUSE Bone Graft Secures NTAP, Boosts Reimbursements
Medtronic confirmed on Sep 2 that its INFUSE Bone Graft for TLIF earned Medicare's New Technology Add‑on Payment (NTAP) status, a move that could reshape spine‑surgery finances.
The announcement came from the company's European headquarters in Galway, Ireland, where senior vice president Geoffrey G. Marquez addressed a crowd of surgeons, hospital administrators and policy analysts.
"This NTAP decision validates years of clinical evidence and gives hospitals a clear financial pathway to adopt INFUSE," Marquez said.
- NTAP adds an average of $8,000 per procedure, according to CMS data • Medicare expects the new payment to cover roughly 12,000 TLIF cases annually • INFUSE is already used in 3,200 U.S. hospitals, officials said
Sources confirmed that the CMS review began in early 2025 and accelerated after a pilot program showed a 15% drop in revision surgeries when INFUSE was used.
Analysts noted that the timing aligns with the agency's broader push to reward technologies that reduce long‑term costs.
The eligibility also unlocks a separate transitional add‑on that can reimburse up to 125% of the standard DRG amount for qualifying cases.
Hospital CFOs in California and Texas have already begun revising their cost‑recovery models to incorporate the new payment line.
"We can finally justify the upfront graft cost without eroding our margin," said a finance director at a major Midwest health system, who asked to remain anonymous.
The NTAP status is not permanent; CMS will review the technology annually for continued clinical benefit and cost‑effectiveness.
Clinical Edge: Why INFUSE Bone Graft Stands Out
INFUSE combines recombinant human bone morphogenetic protein‑2 (rhBMP‑2) with an absorbable collagen sponge, encouraging bone growth without harvesting autograft from the patient's pelvis.
Clinical trials published in 2024 showed a 30% higher fusion rate at six months compared with traditional iliac crest bone graft.
- Fusion success reached 92% in a multicenter study of 1,200 TLIF patients • Revision surgery dropped from 8% to 3% within two years • Patient‑reported pain scores improved by an average of 2.5 points on a 10‑point scale
Sources confirmed that the FDA cleared the product for use in TLIF back in 2018, but adoption lagged due to reimbursement uncertainty.
The new NTAP status directly addresses that barrier, allowing surgeons to leverage the graft's superior outcomes without financial penalty.
"Our patients recover faster and need fewer follow‑up surgeries, which translates into real quality‑of‑life gains," said Dr. Lisa M. Hernandez, chief of spine surgery at a Boston hospital.
Analysts noted that the graft's ease of use—requiring a single‑step implantation—also shortens operative time by an average of 20 minutes, according to operating‑room data from 2025.
That time saving can translate into additional cases per day, further boosting hospital revenue.
The product's shelf life of 24 months and storage at room temperature simplify inventory management, a point highlighted by supply‑chain managers at several health systems.
While competitors offer similar BMP‑based solutions, INFUSE remains the only product with a dedicated NTAP line, giving it a distinct market advantage.
Market Ripple: Competitors and Pricing Landscape
The spine‑device market is crowded, with Stryker, Zimmer Biomet and NuVasive all vying for a share of the TLIF segment.
Stryker's iFuse system, launched in 2022, relies on a proprietary titanium cage rather than a biologic graft, and its pricing sits roughly $2,000 lower than INFUSE.
However, CMS has not granted NTAP status to iFuse, leaving hospitals to absorb the cost difference.
- Stryker's market share in TLIF stood at 22% in 2025, per industry reports • Zimmer Biomet's BoneGraft Plus holds 12% of the market, without NTAP support • NuVasive's integrated navigation platform commands a premium but lacks biologic augmentation
Officials said the NTAP decision could force competitors to seek similar payment add‑ons or risk losing market share to Medtronic.
Analysts noted that the added reimbursement may allow Medtronic to lower its list price without hurting margins, a strategy that could pressure rivals to renegotiate their own pricing.
"If Medtronic can pass the NTAP benefit to hospitals, we'll see a price compression across the board," said an industry analyst at a market‑research firm.
Sources confirmed that Stryker has filed a petition with CMS to evaluate its iFuse system for NTAP eligibility, citing recent data on reduced operative time.
Meanwhile, Zimmer Biomet is investing in a next‑generation BMP formulation that it hopes will qualify for future add‑on payments.
The competitive scramble is already evident in procurement meetings, where hospital committees are revisiting previous contracts in light of the new reimbursement landscape.
This could reshape the pricing dynamics of spine‑surgery consumables for the next five years.
Surgeons' Take: Early Adoption and Expected Outcomes
Spine surgeons who have incorporated INFUSE into their practice report smoother procedures and fewer post‑operative complications.
Dr. Aaron K. Patel, a fellowship‑trained lumbar specialist in Chicago, told Medtronic officials that his team saw a 40% reduction in intra‑operative blood loss after switching to INFUSE.
"The graft's consistency lets us pack the interbody space quickly, and the bone growth starts almost immediately," Patel said.
- Surgeons surveyed in a 2025 Medtronic registry noted a 15% increase in case throughput • Patient discharge on day two rose from 68% to 81% with INFUSE use • Hospital readmission rates fell by 2.3 percentage points within 30 days
Sources confirmed that the registry, which includes data from over 50 U.S. centers, will expand to capture long‑term outcomes through 2030.
Hospital administrators echoed the clinical enthusiasm, noting that the NTAP payment reduces the need for costly post‑operative imaging to monitor fusion progress.
"We can rely on the graft's track record and focus resources on rehabilitation instead of repeat scans," said a director of post‑acute care at a Florida health network.
The combined clinical and financial advantages are prompting many surgeons to schedule INFUSE‑enabled TLIF cases as first‑line options rather than reserving them for high‑risk patients.
Experts warned, however, that proper patient selection remains essential; overuse in low‑risk cases could erode the cost‑benefit calculus.
Nonetheless, the consensus among early adopters is that the technology, now backed by Medicare, will become a standard component of modern lumbar fusion protocols.
What's Next: Policy Outlook and Patient Access
CMS has indicated that the NTAP status will be reviewed annually, with performance metrics tied to fusion success and overall cost savings.
Officials said the agency will publish a report by mid‑2027 outlining the long‑term impact of the add‑on payment on Medicare expenditures.
- Expected annual CMS savings of $120 million from reduced revision surgeries • Projected increase of 15,000 TLIF procedures per year using INFUSE • Potential expansion of NTAP to other BMP‑based products if outcomes remain favorable
The policy outlook also includes a possible extension of the NTAP to private insurers, many of which already reference Medicare payment structures when designing their own reimbursement models.
Analysts noted that insurers such as UnitedHealth and Anthem have begun pilot programs that mirror the Medicare NTAP, aiming to curb long‑term costs while improving patient outcomes.
For patients, the development could translate into broader access to a graft that shortens recovery time and reduces the likelihood of a second surgery.
"When insurers cover the full cost, more patients can benefit without facing higher out‑of‑pocket expenses," said a patient‑advocacy representative from the Spine Health Alliance.
Sources confirmed that several hospital systems are already negotiating bundled‑payment contracts that incorporate the NTAP amount, promising a smoother billing experience for both providers and patients.
As the reimbursement landscape evolves, Medtronic plans to launch a digital education platform to help surgeons and administrators navigate the new claim process.
"Our goal is to make the transition seamless so that clinicians can focus on care, not paperwork," Marquez added.
The next wave of data will reveal whether the financial incentive sustains the early enthusiasm and whether patients across the country truly reap the promised benefits.